Strides Arcolab has received the approval from the United States Food & Drug Administration (US FDA) for Methoxsalen capsules USP, 10 mg (soft gelatin capsules).
According to IMS data, the US market for generic Methoxsalen capsule is approximately USD 13.6 million, with no generic player.
The product will be manufactured at the company’s US FDA approved oral dosage facility at Bengaluru and marketed directly by Strides in the US market.
Methoxsalen is a drug used to treat psoriasis, eczema, vitiligo and some cutaneous lymphomas in conjunction with exposing the skin to UVA light from lamps or sunlight. Methoxsalen modifies the way skin cells receive the UVA radiation, clearing up the disease.
Strides Arcolab develops and manufactures a wide range of IP-led niche pharmaceutical products. The company has five manufacturing facilities presence in more than 75 countries in developed and emerging markets.